Rapid communication Open Access
Like 1


We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0–2.9; B.1.351: 3.6, 95% CI: 2.1–6.2; P.1: 2.6, 95% CI: 1.4–4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4–3.5; P.1: 2.2, 95% CI: 1.7–2.8).


Article metrics loading...

Loading full text...

Full text loading...



  1. Public Health England (PHE). Investigation of novel SARS-CoV-2 variant - variant of concern 202012/01. London: PHE; 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf
  2. European Centre for Disease Prevention and Control (ECDC). Risk assessment: Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update
  3. Japanese National Institute of Infectious Diseases (NIID). Brief report: new variant strain of SARS-CoV-2 identified in travelers from Brazil: Tokyo: NIID; 2021. Available from: https://www.niid.go.jp/niid/en/2019-ncov-e/10108-covid19-33-en.html
  4. Faria NR, Claro IM, Candido D, Franco LAM, Andrade PS, Coletti TM, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological.org. 2021. Available from: https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586
  5. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020:2020.12.21.20248640.  https://doi.org/10.1101/2020.12.21.20248640 
  6. European Centre for Disease Prevention and Control (ECDC). COVID-19 country overviews, week 12/2021, 1 April 2021. Stockholm: ECDC; 2021. Available from: https://covid19-surveillance-report.ecdc.europa.eu/archive-COVID19-reports/archive/2021W12_country_overview_report_20210331.zip
  7. Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, et al. NERVTAG note on B.1.1.7 severity. London: Government Digital Service; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/955239/NERVTAG_paper_on_variant_of_concern__VOC__B.1.1.7.pdf
  8. Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Yssing Michaelsen T, et al. Increased risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark. Preprints with the Lancet. 2021. Available from: https://ssrn.com/abstract=3792894 or http://dx.doi.org/ https://doi.org/10.2139/ssrn.3792894 
  9. Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, CMMID COVID-19 Working Group, Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021.  https://doi.org/10.1038/s41586-021-03426-1  PMID: 33723411 
  10. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372(579):n579.  https://doi.org/10.1136/bmj.n579  PMID: 33687922 
  11. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;NEJMoa2102214.  https://doi.org/10.1056/NEJMoa2102214  PMID: 33725432 
  12. Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv. 2021:2021.01.25.428137.  https://doi.org/10.1101/2021.01.25.428137 
  13. Novel variant incident management team, Public Health England with Imperial College, the University of Edinburgh, the University of Birmingham and the Wellcome Sanger Institute. New evidence on VUI-202012/01 and review of the public health risk assessment. London: Public Health England; 2020. Available from: https://khub.net/documents/135939561/338928724/New+SARS-COV-2+variant+-+information+and+risk+assessment.pdf/b56d4591-0466-1a18-28dc-010e0fdeef53?t=1608569319930
  14. Public Health England (PHE). Investigation of SARS-CoV-2 variants of concern in England. London: PHE; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961299/Variants_of_Concern_VOC_Technical_Briefing_6_England-1.pdf
  15. Borges V, Sousa C, Menezes L, Gonçalves AM, Picão M, Almeida JP, et al. Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021. Euro Surveill. 2021;26(10):2100131.  https://doi.org/10.2807/1560-7917.ES.2021.26.10.2100130  PMID: 33706862 
  16. Robert Koch-Institut (RKI). Risikobewertung zu COVID-19. [Risk assessment of COVID-19]. Berlin: RKI; 2021. German. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Risikobewertung.html
  17. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe (WHO/Europe). Methods for the detection and identification of SARS-CoV-2 variants. Stockholm and Copenhagen: ECDC and WHO/Europe; 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants-WHO-ECDC.pdf
  18. European Centre for Disease Prevention and Control (ECDC). Risk related to spread of new SARSCoV-2 variants of concern in the EU/EEA - 29 December 2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-related-to-spread-of-new-SARS-CoV-2-variants-EU-EEA.pdf

Data & Media loading...

Supplementary data

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error